Archive for the ‘Health Care’ Category
Emergent Announces Initiation of a Phase 1b/2 Study of TRU-016 in Combination with Rituximab and Bendamustine in Subjects with Relapsed – Indolent Lymphoma
ROCKVILLE, Md., Aug 17, 2011 –
Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 1b/2 study (16011) of TRU-016 in combination with rituximab and bendamustine for patients with relapsed indolent non-Hodgkin’s B-cell lymphomas, including follicular lymphoma, small lymphocytic lymphoma and marginal zone lymphoma. TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical(TM) protein therapeutic in development for [...]
In: Chief Medical Officer, Chief executive officer, Clinical Research, Clinical trial, Emergent BioSolutions, Fuad El-Hibri, Health Care · Tagged with: Fuad El-Hibri, Lymphoma, National Cancer Institute, Non-Hodgkin lymphoma
Singapore Health Sciences Authority Approves Emergent BioSolutions Anthrax Vaccine, BioThrax
ROCKVILLE, Md., — Emergent BioSolutions Inc. (NYSE:EBS) announced on June 23rdthat the Singapore Health Sciences Authority (HSA) has approved Emergent’s product license application for the marketing and sale of BioThrax(R) (Anthrax Vaccine Adsorbed) in Singapore. BioThrax is the only vaccine licensed by the U.S. Food and Drug Administration (FDA) to protect against anthrax infection.
“Emergent is [...]
In: Biothrax, Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, Health Care, U.S. Food and Drug Administration · Tagged with: Anthrax vaccines, Biothrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Singapore Ministry of Health
Emergent BioSolutions Announces Initiation of Phase Ib/II Study of TRU-016 in Combination with Bendamustine for Chronic Lymphocytic Leukemia
ROCKVILLE, Md., Jan 25, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced the initiation of a Phase Ib/II study (16201) of TRU-016 for chronic lymphocytic leukemia (CLL). TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical (SMIP(TM)) protein therapeutic in development for the treatment of B-cell malignancies. TRU-016 is [...]
In: Chief executive officer, El-Hibri, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Health Care, Leukemia & Lymphoma Society · Tagged with: American Society of Hematology, Bendamustine, Clinical trial, Emergent Biosolutions Inc, Leukemia, Leukemia & Lymphoma Society, Lymphocyte
Maryland Governor Martin O’Malley Leads Ribbon Cutting Ceremony at Emergent’s Baltimore Manufacturing Facility
ROCKVILLE, MD, July 16, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) today held a ribbon cutting ceremony, led by Governor Martin O’Malley and Fuad El-Hibri, Emergent’s chairman and chief executive officer, to mark the formal opening of Emergent Manufacturing Operations [...]
In: Biothrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Health Care, Management, Research and development, U.S. Food and Drug Administration · Tagged with: Chief executive officer, Emergent BioSolutions, Employment, Fuad El-Hibri, Martin O'Malley, Maryland, United States
Emergent BioSolutions Awarded HHS Contract Valued at Up to $107 Million to Develop Large-Scale Manufacturing for BioThrax
ROCKVILLE, Md., Jul 14, 2010
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract valued at up to $107 million with the Office of the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), to develop and obtain regulatory approval for large-scale [...]
In: Anthrax vaccines, Biothrax, Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, Health Care · Tagged with: Anthrax vaccines, Biothrax, Emergent BioSolutions, Food and Drug Administration, Infectious disease, US government
The El-Hibri Foundation Launches Website
The El-Hibri Foundation is a nonprofit organization with the goal of fostering dialogue between various religions and encouraging nonviolent solutions to global challenges affecting humankind. The Foundation has a new website at www.elhibrifoundation.org.
The Foundation, lead by Chairman of the Board of Trustees Fuad El-HIbri, is divided into [...]
In: Emergent BioSolutions, Foundation, Fuad El-Hibri, Health Care, Peace Education · Tagged with: Chairman, Humanitarian aid, Non-profit organization, Organizations, Philanthropy, Website
Fuad El-Hibri and Healthcare Reform
Fuad El-Hibri serves on the Advisory Board for the Yale Healthcare Conference, a joint effort between the Yale School of Management and the Health Professional Schools at Yale University. The 6th annual healthcare conference was held on April 9, 2010 in New Haven, CT. The conference topic was “Re-Forming Healthcare: Excellence in a Transforming [...]
In: Emergent BioSolutions, Fuad El-Hibri, Health Care, Yale University · Tagged with: Emergent BioSolutions, Fuad El-Hibri, Health Care, United States, Yale University